BioSpace News Archive

Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.

uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.

Recce Pharmaceuticals Ltd announced advances in scaled manufacture and drug quality following positive Food and Drug Administration feedback to its Chemistry, Manufacturing, and Controls data pack.

Recce Pharmaceuticals Ltd announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant Research Hub in Sydney, Australia to combat antimicrobial resistance.

Robocath announces that it has raised €5 million to support the rollout of its robotic platform in strategic European target markets.

Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.

John Houston brings more than 30 years of experience in drug discovery and development in pharma and biotech as Cybrexa prepares to transition to become a clinical-stage company

MLSC’s Milestone Achievement Program awards more than $1.9 million to 10 companies representing all major life sciences sectors

Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.

Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.